Efficacy Study of Aminoflavone Prodrug to Treat Breast Cancer

Phase 2WithdrawnNCT01015521

Tigris Pharmaceuticals50 enrolled

Overview

This is a phase II study to assess the efficacy of Aminoflavone prodrug in triple negative and ER+ breast cancer.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Breast Neoplasm

Interventions

Aminoflavone ProdrugDRUG

Aminoflavone Prodrug administered D1, D8 of 21-day cycle

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * ER+ or TN Breast Cancer * Progression on an aromatase inhibitor if ER+ * Prior treatment with taxane if TN * 18 years or older * Adequate organ function * Measurable lesion Exclusion Criteria: * symptomatic pulmonary disease * brain metastases * pregnant females

Outcomes

Primary Outcomes

Clinical Benefit Response

Time frame: 6 months

Secondary Outcomes

Progression Free Survival

Time frame: 6 monhts

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.